Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Status:
RECRUITING
Trial end date:
2028-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.
Phase:
PHASE2
Details
Lead Sponsor:
German Society for Pediatric Oncology and Hematology GPOH gGmbH